Harmony Biosciences
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological cond...
Latest News
11 days ago · zacks.com
HRMY Q3 Earnings Miss Estimates on Higher Costs Despite Wakix GrowthHarmony Biosciences' Q3 earnings missed estimates as higher costs weighed on profits, while Wakix demand and pipeline progress supported its 2026 revenue outlook.
12 days ago · seekingalpha.com
Harmony Biosciences Holdings, Inc. (HRMY) Q3 2026 Earnings Call TranscriptHarmony Biosciences Holdings, Inc. (HRMY) Q3 2026 Earnings Call Transcript
13 days ago · marketbeat.com
Harmony Biosciences Q3 Earnings Call HighlightsHarmony Biosciences NASDAQ: HRMY reported third-quarter net revenue of $269 million, up from $239 million a year earlier, as demand for its narcolepsy treatment WAKIX continued to grow. The company reiterated its full-year WAKIX net revenue guidance of $1 billion to $1.04 billion and said it expects to exceed $1 billion in annual WAKIX revenue for the first time.
13 days ago · zacks.com
Harmony Biosciences Holdings, Inc. (HRMY) Q3 Earnings and Revenues Lag EstimatesHarmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.81 per share, missing the Zacks Consensus Estimate of $1 per share. This compares to earnings of $0.87 per share a year ago.
20 days ago · zacks.com
Harmony Biosciences Holdings, Inc. (HRMY) Reports Next Week: Wall Street Expects Earnings GrowthHarmony Biosciences (HRMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
26 days ago · zacks.com
HRMY or ARGX: Which Is the Better Value Stock Right Now?Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Harmony Biosciences Holdings, Inc. (HRMY) and argenex SE (ARGX). But which of these two stocks offers value investors a better bang for their buck right now?
26 days ago · zacks.com
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now?Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
26 days ago · barrons.com
Revisiting Former Stock Picks Marriott, Logitech, Harmony BiosciencesTechnical indicators have turned bullish for the Barron's Investor Circle stock picks.
27 days ago · seekingalpha.com
Harmony Biosciences: A Cash Machine With A Patent Ruling Hanging Over ItHarmony Biosciences is rated Buy with a 12-month price target of $43, reflecting strong cash generation and WAKIX growth. HRMY's valuation is supported by WAKIX's robust performance, cash reserves, and limited downside if patents hold through 2030. Key risks include the pending AET patent litigation and management turnover, with significant near-term binary events ahead.
28 days ago · globenewswire.com
Harmony Biosciences to Report Third Quarter 2026 Financial Results on November 4, 2026PLYMOUTH MEETING, Pa., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report third quarter 2026 financial results on Wednesday, November 4, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on November 4, 2026, at 8:30 a.m. ET to discuss the results.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove HRMY